Tuberculous meningitis is a devastating brain infection that is caused by Mycobacterium
tuberculosis and is notoriously difficult to diagnose and treat. New technologies …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Pretomanid is a nitroimidazole antimicrobial active against drug-resistant Mycobacterium
tuberculosis and approved in combination with bedaquiline and linezolid (BPaL) to treat …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are
urgently needed. The landscape of TB treatment has changed considerably over the last …

Background Little is known about the impact of drug-resistance on clinical outcomes among
patients with tuberculosis meningitis (TBM). Methods A retrospective cohort study among …

In 2014, tuberculosis (TB) surpassed HIV as the leading infectious cause of death.
According to the World Health Organization (WHO), there were 10 million incident cases of …

Background The ability of antituberculosis drugs to cross the blood–brain barrier and reach
the central nervous system is critical to their effectiveness in treating tuberculosis meningitis …

Background With current treatment options most patients with CNS TB develop severe
disability or die. Drug-resistant tuberculous meningitis is nearly uniformly fatal. Novel …